Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05198323 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Safety and Efficacy of LT3001 Drug Product in Subjects AIS Undergoing EVT
A Phase 2 study of Acute Ischemic Stroke, sponsored by Lumosa Therapeutics Co..
- Recruiting
- Registry status
- Phase 2
- Development phase
- 66
- Enrollment target
- 2
- Study locations
NCT05198323 is a Phase 2 study of Acute Ischemic Stroke that is actively recruiting participants, run by Lumosa Therapeutics Co.. The registered enrollment target is 66 participants, below the 349-participant average among 25 other Acute Ischemic Stroke trials with a reported enrollment target (81% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT05198323, a Phase 2 study of Acute Ischemic Stroke, is actively recruiting participants, sponsored by Lumosa Therapeutics Co..
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 66 participants
- Enrollment target
- 2
- Study locations
Study Summary
A phase IIb clinical study to evaluate the safety and efficacy of single or multiple doses of LT3001 drug product in subjects with acute ischemic stroke (AIS) undergoing endovascular thrombectomy (EVT).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG LT3001 Drug Product
Study Locations (2)
Tennessee
- CHI Memorial Hospital - Chattanooga
Other
- Taichung Medical University - Taichung
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2022-08-11 |
| Est. Completion | 2026-03-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05198323
The ClinicalTrials.gov registry entry for NCT05198323 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 349-participant average among 25 other Acute Ischemic Stroke trials with a reported enrollment target (81% lower). The listed sponsor is Lumosa Therapeutics Co., which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acute Ischemic Stroke appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05198323 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Tennessee, Other.
Frequently Asked Questions
What is clinical trial NCT05198323 about?
NCT05198323 is a clinical study titled "A Study to Evaluate the Safety and Efficacy of LT3001 Drug Product in Subjects AIS Undergoing EVT". A phase IIb clinical study to evaluate the safety and efficacy of single or multiple doses of LT3001 drug product in subjects with acute ischemic stroke (AIS) undergoing endovascular thrombectomy (EVT).
What is the current status of trial NCT05198323?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 66 participants. The study started on 2022-08-11. Estimated completion is 2026-03-31.
What conditions does trial NCT05198323 study?
This clinical trial studies the following conditions: Acute Ischemic Stroke.
What interventions are being tested in trial NCT05198323?
The interventions under investigation include: Placebo (DRUG), LT3001 Drug Product (DRUG).
Who is sponsoring clinical trial NCT05198323?
This trial is sponsored by Lumosa Therapeutics Co., which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05198323 being conducted?
This trial has 2 study locations across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Ischemic Stroke
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Transcranial Direct Current Stimulation for Treatment of Acute Ischemic Stroke
RECRUITING · Phase 2
-
Optimizing Reperfusion to Improve Outcomes and Neurologic Function
RECRUITING · Phase 2
-
Study of BB-031 in Acute Ischemic Stroke Patients (RAISE)
RECRUITING · Phase 2
-
A Phase 2b, Randomized, Double-blind Study of Redasemtide (S-005151) in Adult Participants With Acute Ischemic Stroke
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Evaluate the Safety and Potential Efficacy of LT3001 Drug Product in Subjects With AIS
COMPLETED · Phase 2
-
A Study to Evaluate the Effects of YM872 on Brain Function and Disability When Administered in Combination With Alteplase (Tissue Plasminogen Activator)
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.